期刊
INTERNATIONAL JOURNAL OF CANCER
卷 147, 期 9, 页码 2479-2492出版社
WILEY
DOI: 10.1002/ijc.33019
关键词
Alpha1-oleate; bladder cancer therapy; dose escalation; lack of toxicity
类别
资金
- HAMLET pharma
- Sharon D Lund foundation
- Gunnar Nilsson Cancer Foundation
- HJ Forssman Foundation for Medical Research
- Royal Physiographic Society
- Inga-Britt and Arne Lundberg Foundation
- Maggie Stephens Foundation
- Medical Faculty (Lund University)
- Soderberg Foundation
- Swedish Cancer Society
Potent chemotherapeutic agents are required to counteract the aggressive behavior of cancer cells and patients often experience severe side effects, due to tissue toxicity. Our study addresses if a better balance between efficacy and toxicity can be attained using the tumoricidal complex alpha1-oleate, formed by a synthetic, alpha-helical peptide comprising the N-terminal 39 amino acids of alpha-lactalbumin and the fatty acid oleic acid. Bladder cancer was established, by intravesical instillation of MB49 cells on day 0 and the treatment group received five instillations of alpha1-oleate (1.7-17 mM) on days 3 to 11. A dose-dependent reduction in tumor size, bladder size and bladder weight was recorded in the alpha1-oleate treated group, compared to sham-treated mice. Tumor markers Ki-67, Cyclin D1 and VEGF were inhibited in a dose-dependent manner, as was the expression of cancer-related genes. Remarkably, toxicity for healthy tissue was not detected in alpha1-oleate-treated, tumor-bearing mice or healthy mice or rabbits, challenged with increasing doses of the active complex. The results define a dose-dependent therapeutic effect of alpha1-oleate in a murine bladder cancer model.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据